Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Randomized Phase 2 Trial of Amcenestrant (SAR439859), Versus Endocrine Monotherapy as Per Physician's Choice in Patients With Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer With Prior Exposure to Hormonal Therapies

NCT04059484 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04059484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04059484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Randomized Phase 2 Trial of Amcenestrant (SAR439859), Versus Endocrine Monotherapy as Per Physician's Choice in Patients With Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer With Prior Exposure to Hormonal Therapies
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Terminated
Start date
October 22, 2019
Completion date
January 2, 2025
Enrollment
367 (actual)
Sites
109

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic